Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All.
Sign Up to like & getrecommendations! Published in 2018 at "Advances in experimental medicine and biology"
DOI: 10.1007/978-3-030-02771-1_8
Abstract: The development of monoclonal antibodies (mAbs) cetuximab and panitumumab, which target the transmembrane protein epidermal growth factor receptor (EGFR), mark a major step forward in the treatment of metastatic colorectal cancer (mCRC). However, this therapeutic… read more here.
Keywords: metastatic colorectal; colorectal cancer; anti egfr; egfr therapy ... See more keywords
Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort
Sign Up to like & getrecommendations! Published in 2017 at "Oncogene"
DOI: 10.1038/onc.2016.283
Abstract: Amplification of the MET oncogene occurs in 2–4% of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have… read more here.
Keywords: met egfr; egfr therapy; resistance; dual met ... See more keywords
Meta-analysis of the effects of anti-epidermal growth factor receptor on recurrent/metastatic head and neck squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Medicine"
DOI: 10.1097/md.0000000000013717
Abstract: Background: We performed a meta-analysis to compare the efficacy and safety of anti-epidermal growth factor receptor (EGFR) therapy and non-anti-EGFR therapy in recurrent/metastatic (RM) head and neck squamous cell carcinoma (HNSCC). Methods: The Cochrane library,… read more here.
Keywords: anti epidermal; anti egfr; egfr therapy; therapy ... See more keywords
Durable complete remission following anti-EGFR antibodies in recurrent metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155217730130
Abstract: In this case report, we describe a patient who remains in complete remission two years after the discontinuation of anti-EGFR monotherapy as a third-line treatment, accompanied by persistent severe hypomagnesemia. A 45-year-old Caucasian woman with… read more here.
Keywords: complete remission; anti egfr; egfr therapy; therapy ... See more keywords
Remodeling of dermal adipose tissue alleviates cutaneous toxicity induced by anti-EGFR therapy
Sign Up to like & getrecommendations! Published in 2022 at "eLife"
DOI: 10.7554/elife.72443
Abstract: Anti-epidermal growth factor receptor (EGFR) therapy–associated cutaneous toxicity is a syndrome characterized by papulopustular rash, local inflammation, folliculitis, and microbial infection, resulting in a decrease in quality of life and dose interruption. However, no effective… read more here.
Keywords: egfr therapy; adipose tissue; cutaneous toxicity;